%0 Journal Article
%T Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients
%A Qiongqiong GAO
%A Xiangli JIANG
%A Chun HUANG
%J Öйú·Î°©ÔÓÖ¾
%D 2017
%R : 10.3779/j.issn.1009-3419.2017.02.07
%X Lung cancer is the leading cause of cancer death in China. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, with the majority of the cases diagnosed at the advanced stage. Molecular targeted therapy is becoming the focus attention for advanced NSCLC. Echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene (EML4-ALK) is among the most common molecular targets of NSCLC; its specific small-molecule tyrosine kinase inhibitors (TKIs) are approved for use in advanced NSCLC cases of ALK-positive. However, the influence of EML4-ALK fusion gene on the outcome of early-stage NSCLC cases and the necessity of application of TKIs for early-stage ALK-positive NSCLC patients are still uncertain. In this paper, we summarized the progression of testing methods for ALK-positive NSCLC patients as well as clinicopathological implication, outcome, and necessity of application of TKIs for early-stage ALK-positive NSCLC patients.
%K Lung neoplasms
%K ALK
%K Testing
%K Clinicopathological implication
%K Outcome
%U http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2017.02.07